A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
SAT0348 Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials
Saturday, 16 JUNE 2018
Conclusions: As early as wk14, IV GLM demonstrated clinically meaningful improvements in skin PsO irrespective of MTX use and nail PsO. Improvement in DLQI was seen as early as wk8, w/continued improvement at wks14 and 24.doi:10.1136/annrheumdis-2018-eular.2132 fatcat:rcgdht4mxzbpnllejp56jgq3zm